

# Trophic Factor Effects on Cholinergic Innervation in the Cerebral Cortex of the Adult Rat Brain

**A. C. Cuello,\* D. Maysinger, and L. Garofalo**

*Department of Pharmacology and Therapeutics, McGill University, 3655 Drummond  
Street, Montreal, Quebec, Canada, H3G 1Y6*

## Contents

Abstract  
Introduction  
NGF Receptor Sites in Cholinergic Neurons  
Morphological, Biochemical, and Functional Plasticity  
of Cholinergic Neurons  
    Anatomical and Biochemical Changes  
    Functional Changes  
Conclusions  
Acknowledgments  
References

## Abstract

The cholinergic pathway ascending from the nucleus basalis magnocellularis (NBM) to the cortex has been implicated in several important higher brain functions such as learning and memory. Following infarction of the frontoparietal cortical area in the rat, a retrograde atrophy of cholinergic cell bodies and fiber networks occurs in the basocortical cholinergic system. We have observed that neuronal atrophy in the NBM induced by this lesion can be prevented by intracerebroventricular administration of exogenous nerve growth factor (NGF) or the monosialoganglioside GM<sub>1</sub>. In addition, these agents can upregulate levels of cortical choline acetyltransferase (ChAT) activity in the remaining cortex adjacent to the lesion site. Furthermore, an enhancement in cortical high-affinity <sup>3</sup>H-choline uptake and a sustained in vivo release of cortical acetylcholine (ACh) after K<sup>+</sup> stimulation are also observed after the application of neurotrophic agents. Moreover, these biochemical changes in the cortex are accompanied by an anatomical remodeling of cortical ChAT-immunoreactive fibers and their synaptic boutons.

**Index Entries:** Nerve growth factor (NGF); nerve growth factor receptor (NGFr); monosialoganglioside (GM<sub>1</sub>); nucleus basalis magnocellularis (NBM); cholinergic synapses; cortex; microdialysis; acetylcholine (ACh) release; high-affinity choline uptake.

\*Author to whom all correspondence and reprint requests should be addressed.

## Introduction

Neurotrophic factors play a fundamental role in the development of the peripheral (PNS) and central nervous systems (CNS). It has been recently demonstrated that in addition to their developmental functions, endogenously produced or exogenously applied neurotrophic agents have pronounced effects in the adult fully differentiated CNS. NGF originally discovered by Rita Levi-Montalcini and coworkers (Levi-Montalcini and Angeletti, 1968), remains the prototype for these responses in the PNS and CNS, and the considerable list of putative neurotrophic agents is continuously growing (for review, see Hefti et al., 1989; Maisonpierre et al., 1990).

As discussed below, some of the most dramatic examples of growth factor effects in the adult CNS have been provided by NGF in the injured cholinergic system. Noncholinergic neuronal populations also respond to growth factors. For example, it has been shown recently that ciliary neurotrophic factor (CNTF) can rescue axotomized spinal motoneurons (Oppenheim et al., 1991) and that brain-derived neurotrophic factor (BDNF) can protect embryonic dopaminergic neurons of the *substantia nigra* from the cytotoxic effects of methyl-phenyl-tetrahydro-pyridine (MPTP) (Hyman et al., 1991). NGF cannot substitute for BDNF or CNTF in these cases. However, studies involving the exogenous administration of trophic factors suggest that different sets of CNS neurons, perhaps independent of the type of transmitter(s) produced by them, are susceptible to the trophic actions of endogenously generated factors, thereby favoring the idea that trophic factors might play a role in reparative attempts of the adult CNS. Interestingly, other agents that are not *bona fide* neurotrophic factors, such as gangliosides, also can protect CNS neurons from injury. Gangliosides have been shown to exert a variety of putative trophic effects on neuronal cells both *in vitro* and *in vivo* (for review, see Skaper et al., 1985; Cuello, 1990).

In this article, we discuss the actions of NGF and the monosialoganglioside GM<sub>1</sub> on the structure and function of the cholinergic presynaptic

terminal network in the injured neocortex of the adult rat. We are particularly pleased to be making a contribution in memory of Eduardo P. De Robertis, a most inspiring forerunner and teacher of A. C. Cuello, a member of our group. De Robertis had a particular interest in cholinergic neurotransmission and greatly contributed to the concept of synaptic vesicle storage and release of neurotransmitters (for review of his early work, see De Robertis, 1964). We would like to think that he would have been delighted to see the progress made in this field, including the discovery of the remarkable plasticity of central cholinergic neurons.

## NGF Receptor Sites in Cholinergic Neurons

Nerve growth factor receptors (NGFr) are presumably synthesized in the neuronal soma and anterogradely transported to nerve terminals; NGFr present in the cholinergic terminal network of the neocortex would bind specifically with NGF, and then the complex is retrogradely transported to the cell soma (Seiler and Schwab, 1984; Taniuchi et al., 1986). The molecular events of NGF's subsequent biological action on the cell remains an issue of intensive investigation. Recently, the high-affinity NGFr has been proposed to comprise two proteins: one, the low-affinity NGFr (p75<sup>NGFR</sup>) and the other, a tyrosine kinase (p140<sup>prototrkr</sup>) encoded by the *trk* proto-oncogene (Kaplan et al., 1991; Hempstead et al., 1991). The monoclonal antibody (MAb) 192-IgG, originally reported by Chandler et al. in 1984 (see also Taniuchi and Johnson, 1985), is thought to recognize the low-affinity form of the receptor, although there is some evidence that it may also recognize the high-affinity form (see below). Several laboratories, including our own, have used this antibody to demonstrate the cellular and subcellular localization of these binding sites (Batchelor et al., 1989; Dawbarn et al., 1988; Eckenstein, 1988; Gomez-Pinilla et al., 1987; Kiss et al., 1988; Koh and Loy, 1989; Pioro and Cuello, 1990; Pioro et al., 1988, 1990; Schweitzer, 1987; Sofroniew et al., 1988; Springer et al., 1987; Yan

and Johnson, 1988). Using light microscopy, we have demonstrated that these sites are closely associated with some CNS cholinergic systems and other noncholinergic sites. Figure 1 illustrates this point.

Since cholinergic neurons of the NBM as well as those of the medial septum are particularly responsive to NGF, it was interesting to investigate the subcellular localization of NGFr-immunoreactive (NGFr-IR) sites in this important forebrain neuronal group. Our ultrastructural studies (Pioro et al., 1990) revealed that immunoperoxidase complexes are present in the rough endoplasmic reticulum (RER), providing unequivocal evidence for local biosynthesis (Fig. 2). Visualization of NGFr-IR in the RER indicates that the epitope recognized by 192-IgG appears very early in the biosynthesis of the receptor. Some of the aggregates of immunoreactive vesicles may represent secondary lysosomes where NGFr is catabolized, whereas others, e.g., in dendrites, may be packaged NGFr's traveling to or from the cell membrane. The patches of more intense NGFr-IR along the cell membrane may be the result of receptor clustering that usually occurs in coated pits prior to internalization (for review, see Brodsky, 1988; Goldstein et al., 1979). The fact that 192-IgG recognizes a site that does not interfere with the binding of NGF at least *in vitro*, permits the possibility of NGF being complexed with the immunolabeled receptor. Our ultrastructural evidence of NGFr internalization indicates that 192-IgG recognizes an epitope that is also present in the high-affinity form of the receptor because low-affinity NGFr apparently is not internalized.

### **Morphological, Biochemical, and Functional Plasticity of Cholinergic Neurons**

#### **Anatomical and Biochemical Changes**

Following infarction of the frontoparietal cortical area in the rat, retrograde atrophy of cholinergic cell bodies and fiber networks occurs in the

basalocortical cholinergic system. Immunocytochemical analysis revealed that ChAT-immunoreactive cells are still visible in the NBM even 120 d after the cortical devascularizing lesion, but are in a shrunken state with retracted dendritic profiles (Sofroniew et al., 1983; Stephens et al., 1985). This lesion (Fig. 3) involves extensive disruption of the pia mater, resulting in a cortical infarct and gradual atrophy of ascending NBM cholinergic fibers, thus differing from the axotomy technique used for the septal-hippocampal pathway. It has been used conveniently to investigate secondary retrograde changes affecting NBM cholinergic neurons when deprived of neuronal targets and their terminal networks.

Several studies have provided evidence for the protective and preventative effects of putative trophic factors at biochemical and morphological levels in this model (Cuello et al., 1989; Cuello, 1990; Maysinger et al., 1990a). More specifically, administration of the monosialoganglioside GM<sub>1</sub>, NGF, or a combination of both administered intracerebroventricularly shortly after lesion prevents the reduction in ChAT enzymatic activity and cholinergic cell shrinkage in the NBM. Even more striking effects were observed in the remaining ipsilateral cortex adjacent to the lesion site where an increase above control values in ChAT enzymatic activity was noted following administration of trophic factors. This suggests that either hyperactivity of the remaining cortical cholinergic terminals occurs as a compensatory mechanism or possibly, that presynaptic terminals are altered morphologically. Both sub-threshold and effective concentrations of the ganglioside GM<sub>1</sub>, when applied in combination with NGF, have supramaximal effects on ChAT activity (Cuello et al., 1989; Garofalo and Cuello, 1990). Cortical ChAT activity largely represents the biosynthetic activity of cholinergic synaptic boutons of fibers ascending from the basal forebrain. Indeed, Garofalo and colleagues (1990) demonstrated, using electron and light microscopic quantitative techniques, that an increase in both cortical ChAT-immunolabeled varicosities and fiber density occurs in lesioned animals treated with GM<sub>1</sub> and NGF simultaneously (Fig. 4a,b).




Fig. 1. Location and LM appearance of NGFr-IR neurons and fibers in the rat CNS. **A:** Schematic representation of sagittally sectioned rat brain, indicating sites of photomicrographs of NGFr-IR neurons and fibers (b–g). **B:** Low-magnification appearance of dense NGFr-IR fiber plexes in the glomerular layer of the main olfactory bulb. G = glomerulus (arrow points to a long-stained fiber within the external plexiform layer). **C:** High-magnification view of scattered NGFr-positive neurons in the caudate putamen (cp); asterisk indicates bundles of unstained myelinated fibers with individual NGFr-IR area (arrowhead). Arrows show NGFr-IR neurons in ventral caudate putamen and more faintly stained ones in the dorsal cp. **D:** Aggregates of NGFr-containing magnocellular neurons of the NBM (arrows); asterisks indicate fibers of the internal capsule. **E:** Darkfield micrograph of NGFr-IR fiber plexes in the hippocampal complex. **f:** Densely stained unipolar neurons of the mesencephalic trigeminal nucleus containing prominent aggregates of NGFr reaction products in perikarya (arrowheads). **g:** High-magnification view of sagittally sectioned cerebellum from a colchicine-treated animal. Arrowheads indicate immunoreactive dendrites of the Purkinje neurons, and arrows point to proximal axons. (Cuello et al., 1990, with permission.)




Fig. 2. Low-magnification EM of an NGFr-IR neuron in the NBM of an adult rat brain. Inset I shows the LM appearance of this neuron in an Epon-embedded semithin section. Asterisks indicate the lumen of the same blood vessel. Prominent NGFr-IR is present in a patchy distribution along the cell membrane (arrowheads). Segments of RER and Golgi bodies (G) also contain reaction product. No specific NGFr-IR is seen in the nucleus (N). 2C indicates distal primary dendrites. 1" high-magnification of NGFr-IR granule. Scale bar for low-magnification EM = 4  $\mu$ m. Inset: 1' = 10  $\mu$ m. Inset 1" = 0.3  $\mu$ m. (Cuello et al., 1990, with permission).

### Functional Changes

Although trophic factor administration to rats with either cortical or NBM lesions can improve biochemical and morphological parameters, a necessary question to address is whether these changes correlate with relevant physiological functions. Marked morphological changes

induced by NGF and GM<sub>1</sub> are accompanied by an increase in high-affinity choline uptake (HACU) over control values in isolated cortical synaptosomes from 30-d postlesion rats. The increments produced by each factor separately (22 and 30%, respectively) were inferior to those noted after combined GM<sub>1</sub> and NGF treatment




Fig. 3. Schematic representation of the cortical lesion. To left: Sagittal rat brain section illustrating the NBM-to-cortex cholinergic pathway and cortical cholinergic interneurons. Top right: The unshaded area within the dashed rectangle represents the brain regions affected by the lesion. These include frontal (fr) 1, and 3, parietal (par) 1, and portions of parietal 2 and occipital (oc) neocortex. The shaded areas indicate brain regions unaffected by the cortical infarction. Cing: cingulate cortex; Retrospl, retrosplenial cortex; Temp, temporal cortex; Pir, piriform cortex; Ent, entorhinal cortex; and Am, amygdaloid body. Bottom left: Schematic appearance of ChAT-IR neurons in the NBM of control unoperated (right) and lesioned animals (left) 30 d postsurgery. Scale bar: 50  $\mu$ m. Bottom right: Effect of the cortical lesion on ChAT activity in various brain areas. Str, striatum; sept, septum; NBM, nucleus basalis magnocellularis; and hipp, hippocampus. \* $p < 0.01$  from control or sham NBM; ANOVA and posthoc Newman-Keul's test.

(66%) (Garofalo and Cuello, 1989). These results are illustrated in Fig. 5, and the findings complement those of DiPatre and collaborators (1989), who showed that treatment with NGF and GM<sub>1</sub> improved cortical choline uptake following NBM lesions.

Further evidence that the morphological and biochemical changes occurring in the remaining ipsilateral cortex of animals treated with GM<sub>1</sub> and NGF may be functionally significant is provided by data from *in vivo* neurotransmitter release studies in fully awake and free-moving animals. Cortical ACh release can be considered indica-

tive of the activity of cholinergic fibers ascending to the cortex. The release of ACh is affected by changes in physiological states and also by a variety of selective drug treatments (Pepeu, 1983).

Cortical ACh output can be modulated either via presynaptic receptors located on cholinergic nerve endings or by altering cholinergic neuronal activity in the NBM. An example of the latter case was provided by Casamenti and coworkers (1986), who by using the cortical cup technique, demonstrated that electrical stimulation of the NBM results in an ipsilateral increase of ACh release from the frontoparietal areas of the cor-




Fig. 4. Morphometric features of cortical cholinergic terminals. **A:** ChAT-IR bouton surface area (expressed in  $\mu\text{m}^2$ ) in cortical layer V of nonlesioned control animals (control) and 30 d postlesion vehicle (veh: artificial CSF + 0.1% BSA),  $\text{GM}_1$  (5 mg/d), NGF (12  $\mu\text{g}/\text{d}$ ), or  $\text{GM}_1/\text{NGF}$ -treated rats. Animals received vehicle or these factors intracerebroventricularly, via minipump, for 7 d beginning immediately postlesion. They were then sacrificed 30 d postlesion (i.e., 23 d after termination of drug administration), and the brains were processed for EM immunocytochemistry. Ultrathin brain sections were obtained, collected on Formvar-coated one slot grids, and observed noncounterstained with a Philips 410 EM. ChAT-IR boutons observed in two grids from separate blocks of each animal were recorded onto video tape and then transferred to an image analysis system (Quantimet 920) where they were automatically detected and measured with the aid of an operator blinded to the treatment groups. Eighty boutons were quantified per group \* $p < 0.01$  from control, ANOVA, and posthoc Newman-Keul's test. **B:** Cortical ChAT-IR fiber number. Four 50  $\mu\text{m}$  thick coronal brain sections at the level of the midbasalis were used for fiber quantification. ChAT-IR profiles were counted with the aid of an image analysis system (Quantimet 920) in all layers of cortex adjacent to the lesion site. veh = vehicle;  $\text{GM}_1$ , NGF, or  $\text{GM}_1/\text{NGF}$  (see A for details). ♦,  $p < 0.01$  from control, lesion + NGF, and lesion +  $\text{GM}_1/\text{NGF}$ -treated groups;  $p < 0.05$  from  $\text{GM}_1$ -treated group. ◇,  $p < 0.01$  from control, and  $p < 0.05$  from lesion + vehicle-treated group. ●,  $p < 0.01$  from lesion + vehicle, and lesion +  $\text{GM}_1/\text{NGF}$ -treated groups. ○,  $p < 0.01$  from control, lesion + vehicle, lesion +  $\text{GM}_1$ , and lesion + NGF-treated groups.

tex. This increase in ACh output (approx 40% on average) was followed by activation of the electrocorticogram. In a series of studies, we used *in vivo* microdialysis (Ungerstedt, 1984; Benveniste, 1989) to study the effects of cortical devascularizing lesions and subsequent treatment with putative neurotrophic agents on basal and stimulated ACh release. A microdialysis probe was implanted diagonally into the anterior portion of the left sensorimotor cortex at a 40° angle. A continuous flow of artificial cerebrospinal fluid (CSF) was delivered (2  $\mu\text{L}/\text{min}$ );

fractions were collected at 20-min intervals and concentrations of ACh were determined using HPLC (Maysinger et al., 1988). Under basal conditions, extracellular cortical ACh concentrations were in the 29–31 nM range in intact, saline-treated controls, and only insignificantly lower in lesioned animals, microdialyzed 30 d following lesion (Fig. 6). Interestingly, the putative trophic agent  $\text{GM}_1$ , administered either locally via biodegradable microspheres or centrally (i.e., intracerebroventricularly) via osmotic minipumps (Alzet 2001), produced an outflow of ACh




Fig. 5. High-affinity choline uptake (HACU) in the ipsilateral remaining cortex of adult rats, following unilateral cortical devascularizing lesion. HACU was determined in synaptosomal preparations (Simon et al., 1976) in four groups of animals: Veh = lesioned receiving (icv) vehicle alone; NGF (12  $\mu$ g/d, 7 d); GM<sub>1</sub> (5 mg/d, 7 d), or both agents in combination (NGF + GM<sub>1</sub>) at the above doses, intracerebroventricularly via minipump. \* $p$  < 0.05 difference from the control nonlesioned animals. □, Ipsilateral CTX; ■, Contra-lateral CTX.

from the adjacent cortex of lesioned animals that was greater than that observed in intact control animals and that was sustained for a prolonged period of time (Fig. 6A) (Maysinger et al., 1990a).

Similarly, NGF administered into the lateral ventricle for 1 wk augmented extracellular ACh above control levels, following both stimulating and nonstimulating conditions (Fig. 6B) (Maysinger et al., 1990b). The decrease in ACh release observed in cortically lesioned vehicle-treated rats might represent an impairment of intrinsic and extrinsic cortical cholinergic systems. Intrinsic cholinergic neurons are spread throughout several layers of the cortex and account for approx 30% of total cortical ACh (Johnston et al., 1981). However, we interpret the




Fig. 6. Release of ACh in vivo. A: Extracellular concentrations of ACh, as determined by HPLC from the rat cortex in nonlesioned (normal) and lesioned animals treated with GM<sub>1</sub> [icv and microencapsulated (micro)]. \* $p$  < 0.05 difference from the lesioned, vehicle-treated, and nonlesioned control animals (ANOVA and posthoc Newman Keul's test). B: Extracellular concentrations of ACh in vivo from the rat cortex in nonlesioned (normal) and lesioned, NGF-treated animals. Black bars = basal conditions (artificial CSF + 10  $\mu$ M neostigmine). Open bars = stimulated conditions (artificial CSF + 10  $\mu$ M neostigmine + 100  $\mu$ M KCl). \* $p$  < 0.05 difference from the lesioned, vehicle-treated, and nonlesioned animals. ■, Basal; □, Stimulated.



decrease in ACh in cortices of lesioned animals to be, for the most part, the result of an impairment of the extrinsic cholinergic innervation to the cortex. Mainly because the remaining ipsilateral cortex received no direct insult, ChAT-positive neurons localized in the NBM ipsilateral to the lesion side are atrophied and biochemical cholinergic deficits are also detected in the microdissected NBM. The fact that GM<sub>1</sub> or NGF treatment enhanced cortical ACh output concurs with the finding that there are NGFr sites in ascending cholinergic fibers in the rat neocortex (Piro and Cuello, 1990) and that GM<sub>1</sub> can facilitate trophic factor-mediated effects (Vantini et al., 1988; Cuello et al., 1989).

## Conclusions

Our experimental data on the cortical lesion model presented here, along with results obtained in several other laboratories using the septohippocampal transection paradigm (Hefti et al., 1986; Williams et al., 1986; Kromer, 1987), demonstrate that exogenous NGF can affect the morphology of cholinergic cell bodies. We are now providing the first, direct morphological evidence that NGF can significantly alter the size of presynaptic cortical cholinergic terminals and suggest the occurrence of significant changes in the number of ChAT-immunoreactive boutons and synapses. These changes correlate with improved cholinergic function substantiated by the increase in HACU and in vivo ACh release noted in these animals. Although the precise mechanism(s) of action of GM<sub>1</sub> and NGF remains unknown, the ability of these agents to alleviate biochemical and morphological cholinergic deficits following brain injury and to induce presynaptic remodeling of cortical cholinergic elements lends support to the view that functional recovery in the CNS of adult animals might be achieved through prolonged and controlled administration of neurotrophic agents. This notion is strengthened by behavioral studies that show an improvement in the performance of trophic factor-treated cortically lesioned rats (Garofalo and Cuello,

1990; Elliot et al., 1989). In summary, the ability of NGF to mediate synaptic plasticity in the adult and fully differentiated CNS demonstrates that neuronal connections can be potentially induced and exogenously manipulated, thus opening new avenues for regeneration studies involving the mature CNS.

## Acknowledgments

The authors wish to acknowledge support from the Medical Research Council of Canada, the Canadian Centres of Excellence Network for Neural Regeneration and Functional Recovery, Fonds de la recherche en santé du Québec, and Fidia Research Laboratories, who also provided the ganglioside GM<sub>1</sub>. We also thank Diane Plant and Christina Kuszynski for editorial and secretarial assistance and Alan Forster for his photographic expertise.

## References

- Batchelor P. E., Armstrong D. M., Blaker S. N., and Gage F. H. (1989) Nerve growth factor receptor and choline acetyltransferase colocalization in neurons within the rat forebrain: response to fimbria-fornix transection. *J. Comp. Neurol.* **284**, 187–204.
- Benveniste H. (1989) Brain microdialysis. *J. Neurochem.* **52**, 1667–1679.
- Brodsky F. M. (1988) Living with clathrin: its role in intracellular membrane traffic. *Science* **242**, 1396–1402.
- Casamenti F., Deffenu G., Abbamondi A. L., and Pepeu G. (1986) Changes in cortical acetylcholine output induced by modulation of the nucleus basalis. *Brain Res. Bull.* **16**, 689–695.
- Chandler C. E., Parsons LM., Hosang M., and Shooter E. M. (1984) A monoclonal antibody modulates the interaction of nerve growth factor with PC12 cells. *J. Biol. Chem.* **259**, 6882–6889.
- Cuello A. C. (1990) Glycosphingolipids that can regulate nerve growth and repair, *Advances in Pharmacology*, Academic, New York, pp. 1–50.
- Cuello A. C., Garofalo L., Kenigsberg R. L., and Maysinger D. (1989) Gangliosides potentiate *in vivo*

- and *in vitro* effects of nerve growth factor on central cholinergic neurons. *Proc. Natl. Acad. Sci. USA* **86**, 2056–2060.
- Cuello A. C., Pioro E. P., and Ribeiro-da-Silva A. (1990) Cellular and subcellular localization of nerve growth factor receptor-like immunoreactivity in the rat CNS. *Neurochem. Int.* **17**, 205–213.
- Dawbarn D., Allen S. J., and Semenenko F. M. (1988) Coexistence of choline acetyltransferase and nerve growth factor receptors in the rat basal forebrain. *Neurosci. Lett.* **94**, 138–144.
- DeRobertis E. P. (1964) *Histophysiology of Synapses and Neurosecretion*, Pergamon, Oxford, UK.
- DiPatre P. L., Casamenti F., Cenni A., and Pepeu G. (1989) Interaction between nerve growth factor and GM<sub>1</sub> monosialoganglioside in preventing cortical choline acetyltransferase and high-affinity choline uptake decrease after lesion of the nucleus basalis. *Brain Res.* **480**, 219–224.
- Eckenstein F. (1988) Transient expression of NGF-receptor-like immunoreactivity in postnatal rat brain and spinal cord. *Brain Res.* **446**, 149–154.
- Elliott P. J., Garofalo L., and Cuello A. C. (1989) Limited neocortical devascularizing lesions causing deficits in memory retention and choline acetyltransferase activity: effects of the monosialoganglioside GM<sub>1</sub>. *Neuroscience* **31**, 63–76.
- Garofalo L. and Cuello A. C. (1989) Effects of NGF and/or GM<sub>1</sub> on high-affinity choline uptake in the rat brain following unilateral decortication. *Soc. Neurosci. Abstr.* **15**, 867.
- Garofalo L. and Cuello A. C. (1990) Nerve growth factor and the monosialoganglioside GM<sub>1</sub> modulate cholinergic markers and affect behavior of decorticated adult rats. *Euro. J. Pharmacol.* **183**, 934.
- Goldstein J. L., Anderson R. G. W., and Brown M. S. (1979) Coated pits, coated vesicles and receptor-mediated endocytosis. *Nature* **279**, 679–685.
- Gomez-Pinilla F., Cotman C. W., and Nieto-Sampedro M. (1987) NGF-receptor immunoreactivity in rat brain: topographical distribution and response to entorhinal ablation. *Neurosci. Lett.* **82**, 260–266.
- Hefti F., Hartikka J., and Knusel B. (1989) Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. *Neurobiol. Aging* **10**(5), 515–533.
- Hefti F., Hartikka J., Salvatierra A., Weiner W. J., and Mash D. C. (1986) Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. *Neurosci. Lett.* **69**, 37–41.
- Hempstead B. L., Martin-Zanca D., Kaplan D. R., Parada L. F., and Chao M. V. (1991) High-affinity NGF-binding requires coexpression of the *trk* protooncogene and the low-affinity NGF receptor. *Nature* **350**, 678–683.
- Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D., Squinto S. P., and Lindsay R. M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature* **350**, 230–232.
- Johnston M. V., McKinney M., and Coyle J. T. (1981) Neocortical cholinergic innervation: a description of extrinsic and intrinsic components in the rat. *Expl. Brain Res.* **43**, 159–172.
- Kaplan D. R., Hempstead B. L., Martin-Zanca D., Chao M. V., and Parada L. F. (1991) The *trk* protooncogene product: a signal transducing receptor for nerve growth factor. *Science* **252**, 554–558.
- Kiss J., McGovern J., and Patel A. J. (1988) Immunohistochemical localization of cells containing nerve growth factor receptors in the different regions of the adult rat forebrain. *Neuroscience* **27**, 731–748.
- Koh S. and Loy R. (1989) Localization and development of nerve growth factor-sensitive rat basal forebrain neurons and their afferent projections to hippocampus and neocortex. *J. Neurosci.* **9**, 2999–3018.
- Kromer L. F. (1987) Nerve growth factor treatment after brain injury prevents neuronal death. *Science* **235**, 214–216.
- Levi-Montalcini R. and Angeletti P. U. (1968) Nerve growth factor. *Physiol. Rev.* **48**, 534–569.
- Maisonpierre P. C., Belluscio L., Squinto S., Ip N. Y., Furth M. E., Lindsay R. M., and Yancopoulos G. D. (1990) Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. *Science* **247**, 1446–1451.
- Maysinger D., Herrera-Marschitz M., Carlsson A., Garofalo L., Ungerstedt U., and Cuello A. C. (1988) Striatal and cortical acetylcholine release *in vivo* in rats with unilateral decortication: effects of treatment with monosialoganglioside GM<sub>1</sub>. *Brain Res.* **461**, 355–360.
- Maysinger D., Herrera-Marschitz M., Ungerstedt U., and Cuello A. C. (1990a) Acetylcholine release *in vivo*: effects of chronic treatment with monosialoganglioside GM<sub>1</sub>. *Neuropharmacology* **29**(2), 151–159.
- Maysinger D., Herrera-Marschitz M., Ungerstedt U., and Cuello A. C. (1990b) Release of acetylcholine from cerebral cortex *in vivo*: effects of NGF and GM<sub>1</sub>. *Euro. J. Pharmacol.* **83**(3), 935.

- Oppenheim R. W., Prevette D., Qin-Wei Y., Collins F., and MacDonald J. (1991) Control of embryonic motoneuron survival *in vivo* by ciliary neurotrophic factor. *Science* **251**, 1616–1618.
- Pepeu G. (1983) Brain acetylcholine: an inventory of our knowledge on the 50th anniversary of its discovery. *Trends Pharmacol. Sci.* **4**, 416–418.
- Piolo E. P. and Cuello A. C. (1990) Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic system: forebrain. *Neuroscience* **34**, 57–87.
- Piolo E. P., Ribeiro-da-Silva A., and Cuello A. C. (1988) Electron microscopy of nerve growth factor receptor immunoreactivity in cerebellar Purkinje cells of adult rats pretreated with colchicine. *Abstr. Soc. Neurosci.* **14**, 903.
- Piolo E. P., Ribeiro-da-Silva A., and Cuello A. C. (1990) Immunoelectron microscopic evidence of nerve growth factor receptor metabolism and internalization in rat nucleus basalis neurons. *Brain Res.* **527**, 109–115.
- Schweitzer J. B. (1987) Nerve growth factor receptor-mediated transport from cerebrospinal fluid to basal forebrain neurons. *Brain Res.* **423**, 309–317.
- Seiler M. and Schwab M. E. (1984) Specific retrograde transport of nerve growth factor from neocortex to nucleus basalis in the rat. *Brain Res.* **300**, 33–39.
- Simon J. R., Atweh S., and Kuhar M. J. (1976) Sodium dependent high-affinity choline uptake: a regulatory step in the synthesis of acetylcholine. *J. Neurochem.* **26**, 909–922.
- Skaper S. D., Katoh-Semba R., and Varon S. (1985) GM<sub>1</sub> ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selective culture conditions. *Dev. Brain Res.* **23**, 19–26.
- Sofroniew M. V., Isaacson O., and O'Brien T. S. (1988) Nerve growth factor receptor immunoreactivity in the rat suprachiasmatic nucleus. *Brain Res.* **476**, 358–362.
- Sofroniew M. V., Pearson R. C. A., Eckenstein F., Cuello A. C., and Powell T. P. S. (1983) Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage. *Brain Res.* **289**, 370–374.
- Springer J. E., Koh S., Tayrien M. W., and Loy R. (1987) Basal forebrain magnocellular neurons stain for nerve growth factor receptor: correlation with cholinergic cell bodies and effects of axotomy. *J. Neurosci. Res.* **17**, 111–118.
- Stephens P. H., Cuello A. C., Sofroniew M. V., Pearson R. C. A., and Tagari P. (1985) Effect of unilateral decortication on choline acetyltransferase activity in the nucleus basalis and other areas of the rat brain. *J. Neurochem.* **45**, 1021–1026.
- Taniuchi M. and Johnson E. M. Jr. (1985) Characterization of the binding properties and retrograde axonal transport of a monoclonal antibody directed against the rat nerve growth factor receptor. *J. Cell Biol.* **101**, 1100–1106.
- Taniuchi M., Schweitzer J. B., and Johnson E. M. Jr. (1986) Nerve growth factor receptor molecules in rat brain. *Proc. Natl. Acad. Sci. USA* **83**, 1950–1954.
- Ungerstedt U. (1984) Measurement of neurotransmitter release by intracranial dialysis, *Measurement of Neurotransmitter Release In Vivo*, Wiley, New York, pp. 81–107.
- Vantini G., Fusco M., Bigon E., and Leon A. (1988) GM<sub>1</sub> ganglioside potentiates the effect of nerve growth factor in preventing vinblastine induced sympathectomy in newborn rats. *Brain Res.* **448**, 252–258.
- Williams L. R., Varon S., Peterson G. M., Victorin K., Fischer W., Björklund A., and Gage F. H. (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. *Proc. Natl. Acad. Sci. USA* **83**, 9231–9235.
- Yan Q. and Johnson E. M. Jr. (1988) An immunohistochemical study of the nerve growth factor receptor in developing rats. *J. Neurosci.* **8**, 3481–3498.